|
Myeloid Neoplasia
Citations 41-50 of 176 total displayed.
|
Past content
(since Jan 2009):
|
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
- Tamer E. Fandy, James G. Herman, Patrick Kerns, Anchalee Jiemjit, Elizabeth A. Sugar, Si-Ho Choi, Allen S. Yang, Timothy Aucott, Tianna Dauses, Rosalie Odchimar-Reissig, Jonathan Licht, Melanie J. McConnell, Chris Nasrallah, Marianne K. H. Kim, Weijia Zhang, Yezou Sun, Anthony Murgo, Igor Espinoza-Delgado, Katharine Oteiza, Ibitayo Owoeye, Lewis R. Silverman, Steven D. Gore, and Hetty E. Carraway
Blood 2009; 114: 2764-2773.
[Abstract]
[Full text]
[PDF]
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome
- Sabine Kayser, Richard F. Schlenk, Martina Correa Londono, Frank Breitenbuecher, Kerstin Wittke, Juan Du, Silja Groner, Daniela Späth, Jürgen Krauter, Arnold Ganser, Hartmut Döhner, Thomas Fischer, Konstanze Döhner, and for the German-Austrian AML Study Group (AMLSG)
Blood 2009; 114: 2386-2392.
[Abstract]
[Full text]
[PDF]
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
- Peter L. Greenberg, Zhuoxin Sun, Kenneth B. Miller, John M. Bennett, Martin S. Tallman, Gordon Dewald, Elisabeth Paietta, Richard van der Jagt, Jessie Houston, Mary L. Thomas, David Cella, and Jacob M. Rowe
Blood 2009; 114: 2393-2400.
[Abstract]
[Full text]
[PDF]
Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C
- Maike Schwieger, Andrea Schüler, Martin Forster, Afra Engelmann, Michael A. Arnold, Ruud Delwel, Peter J. Valk, Jürgen Löhler, Robert K. Slany, Eric N. Olson, and Carol Stocking
Blood 2009; 114: 2476-2488.
[Abstract]
[Full text]
[PDF]
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study
- Brian V. Balgobind, Susana C. Raimondi, Jochen Harbott, Martin Zimmermann, Todd A. Alonzo, Anne Auvrignon, H. Berna Beverloo, Myron Chang, Ursula Creutzig, Michael N. Dworzak, Erik Forestier, Brenda Gibson, Henrik Hasle, Christine J. Harrison, Nyla A. Heerema, Gertjan J. L. Kaspers, Anna Leszl, Nathalia Litvinko, Luca Lo Nigro, Akira Morimoto, Christine Perot, Rob Pieters, Dirk Reinhardt, Jeffrey E. Rubnitz, Franklin O. Smith, Jan Stary, Irina Stasevich, Sabine Strehl, Takashi Taga, Daisuke Tomizawa, David Webb, Zuzana Zemanova, C. Michel Zwaan, and Marry M. van den Heuvel-Eibrink
Blood 2009; 114: 2489-2496.
[Abstract]
[Full text]
[PDF]
Minimal residual disease levels assessed by NPM1 mutation–specific RQ-PCR provide important prognostic information in AML
- Susanne Schnittger, Wolfgang Kern, Claudia Tschulik, Tamara Weiss, Frank Dicker, Brunangelo Falini, Claudia Haferlach, and Torsten Haferlach
Blood 2009; 114: 2220-2231.
[Abstract]
[Full text]
[PDF]
Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance
- Dushyant Verma, Hagop M. Kantarjian, Dan Jones, Rajyalakshmi Luthra, Gautam Borthakur, Srdan Verstovsek, Mary Beth Rios, and Jorge Cortes
Blood 2009; 114: 2232-2235.
[Abstract]
[Full text]
[PDF]
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
- Elias Jabbour, Daniel Jones, Hagop M. Kantarjian, Susan O'Brien, Constantine Tam, Charles Koller, Jan A. Burger, Gautam Borthakur, William G. Wierda, and Jorge Cortes
Blood 2009; 114: 2037-2043.
[Abstract]
[Full text]
[PDF]
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
- Simona Soverini, Alessandra Gnani, Sabrina Colarossi, Fausto Castagnetti, Elisabetta Abruzzese, Stefania Paolini, Serena Merante, Ester Orlandi, Silvia de Matteis, Antonella Gozzini, Ilaria Iacobucci, Francesca Palandri, Gabriele Gugliotta, Cristina Papayannidis, Angela Poerio, Marilina Amabile, Daniela Cilloni, Gianantonio Rosti, Michele Baccarani, and Giovanni Martinelli
Blood 2009; 114: 2168-2171.
[Abstract]
[Full text]
[PDF]
Granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)
- Ivan M. Borrello, Hyam I. Levitsky, Wendy Stock, Dorie Sher, Lu Qin, Daniel J. DeAngelo, Edwin P. Alyea, Richard M. Stone, Lloyd E. Damon, Charles A. Linker, Daniel J. Maslyar, and Kristen M. Hege
Blood 2009; 114: 1736-1745.
[Abstract]
[Full text]
[PDF]
|
|
